Number 679 • March 2017

National Poison Prevention Week is March 19 to 25—help to protect children from medication poisoning

Consider a few key figures:

- In 2015, the Poison and Drug Information Service (PADIS) received more than 15,600 calls from individuals concerned that a child had been poisoned.
- In 2014, 1,750 children under the age of 10 visited emergency departments due to unintentional poisoning. Prescription medication was involved in seven out of 10 of these visits.

Improperly-stored medications are the leading cause of childhood poisoning in Alberta. As a pharmacy, you are well-equipped to provide valuable information on the safe storage of prescription and over-the-counter medications to parents and caregivers in your community during Poison Prevention Week.

Check out the guidebook

The Injury Prevention Centre's guidebook was created to improve awareness of medication poisoning and increase prevention of medication-related poisonings in children. The information in this guidebook is geared towards parents, grandparents and caregivers. It includes engaging activities and provides readers with tools to better protect those in their care who may be vulnerable to medication-related poisoning.

The Injury Prevention Centre's guidebook is available online at no cost. Just visit injurypreventioncentre.ca/programs/poison_prevention, navigate to the 'Community Promoters' tab and click on the green 'Download the guidebook' button.

Access free campaign materials

To highlight this year's provincial campaign and help raise awareness of poison prevention, you can order free materials from the Injury Prevention Centre. Keep in mind that these materials are not dated and can be used throughout the year.

There is no charge for the materials; all that's required is your feedback so that the Injury Prevention Centre can continue to strengthen their educational efforts across the province. They will provide you with a short survey once the campaign concludes.

To order campaign resources, go to injurypreventioncentre.ca/programs/poison_prevention, navigate to the 'Community Promoters' tab and click on the green 'Order resources' button.

The key messages of poison prevention

- · Store all medications so that they are tightly locked and out of sight.
- Take your medications in a place that is out of sight of children.
- · Keep visitors' bags and coats out of reach.
- Program the number for Poison and Drug Information Service (PADIS) into your phone. The PADIS number is 1-800-332-1414.

For more information about the campaign, visit the www.injurypreventioncentre.ca/programs/poison_prevention or contact Patti Stark at patti.stark@ualberta.ca.

Removal of temporary benefits from the Alberta Drug Benefit List (ADBL)

Due to the shortages of the following products:

DIN	Product description	Manufacturer
02393581	Act Nabilone 0.5 mg Capsule	Actavis Pharma Company
02380900	pms-Nabilone 0.5 mg Capsule	Pharmascience Inc.
02358085	Ran-Nabilone 0.5 mg Capsule	Ranbaxy Pharmaceuticals Canada Inc
02384884	Teva-Nabilone 0.5 mg Capsule	Teva Canada Limited
02256193	Cesamet 0.5 mg Capsule	Valeant Canada LP
02393603	Act Nabilone 1 mg Capsule	Actavis Pharma Company
02380919	pms-Nabilone 1 mg Capsule	Pharmascience Inc.
02358093	Ran-Nabilone 1 mg Capsule	Ranbaxy Pharmaceuticals Canada Inc
02384892	Teva-Nabilone 1 mg Capsule	Teva Canada Limited
00548375	Cesamet 1 mg Capsule	Valeant Canada LP

Ran-Nabilone 0.25 mg Capsule (DIN 02358077), manufactured by Ranbaxy Pharmaceuticals Canada Inc, Teva-Nabilone 0.25 mg Capsule (DIN 02392925) manufactured by Teva Canada Limited and Cesamet 0.25 mg Capsule (DIN 02312263) manufactured by Valeant Canada LP were added as temporary benefits for the Alberta Drug Benefit List (ADBL).

Valeant Canada LP has advised Alberta Blue Cross that the shortages of Cesamet 0.5 mg Capsule (DIN 02256193) and Cesamet 1 mg Capsule (DIN 00548375) have been resolved.

As a result, Ran-Nabilone 0.25 mg Capsule (DIN 02358077), Teva-Nabilone 0.25 mg Capsule (DIN 02392925) and Cesamet 0.25 mg Capsule (DIN 02312263) will no longer be considered temporary benefits for the ADBL **after April 7, 2017.**

Due to the shortages of pms-Oxycodone 5 mg Tablet (DIN 02319977) manufactured by Pharmascience Inc. and Supeudol 5 mg Tablet (DIN 00789739) manufactured by Sandoz Canada Inc., Oxy-IR 5 mg Tablet (DIN 02231934) manufactured by Purdue Pharma was added as a temporary benefit for the Alberta Drug Benefit List (ADBL).

Pharmascience Inc. and Sandoz Canada Inc. have advised Alberta Blue Cross that the shortages of pms-Oxycodone 5 mg Tablet (DIN 02319977) and Supeudol 5 mg Tablet (DIN 00789739) have been resolved.

As a result, Oxy-IR 5 mg Tablet (DIN 02231934) will no longer be considered a temporary benefit for the ADBL after April 7, 2017.

Product supply shortage addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Pharmascience Inc. that the shortage for of pms-Oxycodone 5 mg Tablet (DIN 02319977) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 7, 2017.**

OXYCODONE HCL

5 MG TABLET

00002319977	PMS-OXYCODONE	PMS	\$ 0.1287
00000789739	SUPEUDOL	SDZ	\$ 0.1332

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit https://www.ab.bluecross.ca/providers/pharmacy-home.php**



